Mice with TNBS-induced colitis who were given an FMT from CD patients who achieved remission with vedolizumab exhibited elevated CDCA and LCA levels, leading to increased stimulation of FXR and TGR5, and ultimately alleviating colitis [122]. This evidence concerns the gene NR1H4 and colitis.